In clinical trial NCT02493530, the combination of umbralisib and ruxolitinib (a JAK1/2 inhibitor) attained an ORR of 56.5% in ruxolitinib-resistant myelofibrosis patients, including two cases of complete remissions. The gene discussed is JAK1; the disease is myelofibrosis.